Literature DB >> 15747063

Anti-glioma action of aloe emodin: the role of ERK inhibition.

S Mijatovic1, D Maksimovic-Ivanic, J Radovic, Dj Miljkovic, Lj Harhaji, O Vuckovic, S Stosic-Grujicic, M Mostarica Stojkovic, V Trajkovic.   

Abstract

The effect of aloe emodin (AE), a herbal anthraquinone derivative, on the rat C6 glioma cell line was investigated. In addition to cell cycle block and caspasedependent apoptosis, AE led to the formation of intracytoplasmic acidic vesicles indicative for autophagic cell death. Moreover, differentiation of surviving cells toward the astrocytic lineage was confirmed by typical morphological changes and increased expression of glial fibrillary acidic protein (GFAP). AE did not affect the activation of mitogen-activated protein kinase p38, Jun-N-terminal kinase, or transcription factor NF-kappaB, but markedly inhibited the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in C6 cells. A selective inhibitor of ERK activation, PD98059, mimicked the effects of AE on glioma cell morphology and GFAP expression, but failed to induce either apoptosis or autophagy. Taken together, these results indicate that the anti-glioma action of AE involves ERK-independent induction of both apoptosis and autophagy, as well as ERK inhibition-mediated differentiation of glioma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747063     DOI: 10.1007/s00018-005-4425-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  24 in total

1.  The off-hours paradigm in primary PCI can be overcome by a uniform regional treatment protocol.

Authors:  Ralf Birkemeyer; Andreas Rillig; Tomislav Miljak; Udo Meyerfeldt; Erhard Kaiser; Werner Jung; Jochen Wöhrle
Journal:  Int J Cardiol       Date:  2012-04-17       Impact factor: 4.164

2.  High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission.

Authors:  Evangelos Giannitsis; Meike Becker; Kerstin Kurz; Georg Hess; Dietmar Zdunek; Hugo A Katus
Journal:  Clin Chem       Date:  2010-02-18       Impact factor: 8.327

3.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Christian W Hamm; Jean-Pierre Bassand; Stefan Agewall; Jeroen Bax; Eric Boersma; Hector Bueno; Pio Caso; Dariusz Dudek; Stephan Gielen; Kurt Huber; Magnus Ohman; Mark C Petrie; Frank Sonntag; Miguel Sousa Uva; Robert F Storey; William Wijns; Doron Zahger
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

4.  Pre- and early in-hospital procedures in patients with acute coronary syndromes: first results of the "German chest pain unit registry".

Authors:  Felix Post; Evangelos Giannitsis; Thomas Riemer; Lars S Maier; Claus Schmitt; Burghard Schumacher; Gerd Heusch; Harald Mudra; Thomas Voigtländer; Rainer Erbel; Harald Darius; Hugo Katus; Christian Hamm; Jochen Senges; Tommaso Gori; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2012-07-25       Impact factor: 5.460

5.  Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial).

Authors:  Holger Thiele; Justus Rach; Norbert Klein; Dietrich Pfeiffer; Andreas Hartmann; Rainer Hambrecht; Peter Sick; Ingo Eitel; Steffen Desch; Gerhard Schuler
Journal:  Eur Heart J       Date:  2011-11-21       Impact factor: 29.983

6.  Establishment and progress of the chest pain unit certification process in Germany and the local experiences of Mainz.

Authors:  Felix Post; Tommaso Gori; Jochen Senges; Evangelos Giannitsis; Hugo Katus; Thomas Münzel
Journal:  Eur Heart J       Date:  2012-03       Impact factor: 29.983

7.  Timing of percutaneous coronary intervention in troponin-negative patients with acute coronary syndrome without persistent ST-segment elevation: preliminary results and status quo in German chest pain units.

Authors:  Frank Breuckmann; Matthias Hochadel; Thomas Münzel; Evangelos Giannitsis; Thomas Voigtländer; Jochen Senges
Journal:  Crit Pathw Cardiol       Date:  2015-03

8.  Use of the Centaur TnI-Ultra assay for detection of myocardial infarction and adverse events in patients presenting with symptoms suggestive of acute coronary syndrome.

Authors:  Fred S Apple; Stephen W Smith; Lesly A Pearce; Ranka Ler; Maryann M Murakami
Journal:  Clin Chem       Date:  2008-01-31       Impact factor: 8.327

9.  Weekend versus weekday admission and mortality from myocardial infarction.

Authors:  William J Kostis; Kitaw Demissie; Stephen W Marcella; Yu-Hsuan Shao; Alan C Wilson; Abel E Moreyra
Journal:  N Engl J Med       Date:  2007-03-15       Impact factor: 91.245

10.  Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.

Authors:  Charles V Pollack; Judd E Hollander; Anita Y Chen; Eric D Peterson; Sripal Bangalore; Frank W Peacock; Christopher P Cannon; John G Canto; Brian W Gibler; Magnus E Ohman; Matthew T Roe
Journal:  Crit Pathw Cardiol       Date:  2009-03
View more
  21 in total

1.  Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation.

Authors:  Xiaobin Chang; Jimin Zhao; Fang Tian; Yanan Jiang; Jing Lu; Junfen Ma; Xiaoyan Zhang; Guoguo Jin; Youtian Huang; Zigang Dong; Kangdong Liu; Ziming Dong
Journal:  Oncol Lett       Date:  2016-07-25       Impact factor: 2.967

2.  Membrane fluidity, invasiveness and dynamic phenotype of metastatic prostate cancer cells after treatment with soy isoflavones.

Authors:  Vladimir Ajdžanović; Marija Mojić; Danijela Maksimović-Ivanić; Mirna Bulatović; Sanja Mijatović; Verica Milošević; Ivan Spasojević
Journal:  J Membr Biol       Date:  2013-02-16       Impact factor: 1.843

3.  Anti-tumor effect of emodin on gynecological cancer cells.

Authors:  Yaoxian Wang; Hui Yu; Jin Zhang; Xin Ge; Jing Gao; Yunyan Zhang; Ge Lou
Journal:  Cell Oncol (Dordr)       Date:  2015-07-11       Impact factor: 6.730

4.  Design and evaluation of new chemotherapeutics of aloe-emodin (AE) against the deadly cancer disease: an in silico study.

Authors:  Chaitanya Mulakayala; Babajan Banaganapalli; Naveen Mulakayala; Madhusudana Pulaganti; Anuradha C M; Suresh Kumar Chitta
Journal:  J Chem Biol       Date:  2013-05-23

5.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

6.  Emodin ameliorates cisplatin-induced apoptosis of rat renal tubular cells in vitro by activating autophagy.

Authors:  Hong Liu; Liu-bao Gu; Yue Tu; Hao Hu; Yan-ru Huang; Wei Sun
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

Review 7.  Aloe and its Effects on Cancer: A Narrative Literature Review.

Authors:  Astère Manirakiza; Laurent Irakoze; Sebastien Manirakiza
Journal:  East Afr Health Res J       Date:  2021-06-11

8.  Tripchlorolide induces cell death in lung cancer cells by autophagy.

Authors:  Limin Chen; Qing Liu; Zhenghui Huang; Feng Wu; Zhiying Li; Xiangqi Chen; Tingyan Lin
Journal:  Int J Oncol       Date:  2011-12-01       Impact factor: 5.650

9.  Safety of traditional arab herbal medicine.

Authors:  Bashar Saad; Hassan Azaizeh; Ghassan Abu-Hijleh; Omar Said
Journal:  Evid Based Complement Alternat Med       Date:  2006-09-07       Impact factor: 2.629

10.  On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy.

Authors:  Santiago Gómez-Ruiz; Danijela Maksimović-Ivanić; Sanja Mijatović; Goran N Kaluđerović
Journal:  Bioinorg Chem Appl       Date:  2012-07-12       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.